| Typicality: | 0.572 |
| Saliency: | 0.376 |
| against other cancers | 8 | transitive-object |
| in the last few years | 3 | temporal |
| recently | 2 | temporal |
| antibody → be approved for → use | 7 |
| antibody → be approved by → the fda | 7 |
| antibody → be → approved | 4 |
| antibody → be approved at → this stage | 3 |
| negative | neutral | positive |
| 0.010 | 0.533 | 0.457 |
| Raw frequency | 21 |
| Normalized frequency | 0.376 |
| Modifier score | 1.000 |
| Perplexity | 393.991 |